Verastem Company Profile (NASDAQ:VSTM)

About Verastem (NASDAQ:VSTM)

Verastem logoVerastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:VSTM
  • CUSIP: 92337C10
  • Web:
  • Market Cap: $196.8 million
  • Outstanding Shares: 36,992,000
Average Prices:
  • 50 Day Moving Avg: $3.98
  • 200 Day Moving Avg: $2.71
  • 52 Week Range: $1.05 - $5.71
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.30
  • P/E Growth: -2.24
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.30 per share
  • Price / Book: 3.96
  • EBIDTA: ($45,870,000.00)
  • Return on Equity: -69.88%
  • Return on Assets: -59.24%
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 5.40%
  • Quick Ratio: 5.40%
  • Average Volume: 1.60 million shs.
  • Beta: 2.27
  • Short Ratio: 1.47

Frequently Asked Questions for Verastem (NASDAQ:VSTM)

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.02. View Verastem's Earnings History.

When will Verastem make its next earnings announcement?

Verastem is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Verastem.

Where is Verastem's stock going? Where will Verastem's stock price be in 2017?

6 analysts have issued 1-year target prices for Verastem's stock. Their forecasts range from $1.50 to $10.00. On average, they anticipate Verastem's stock price to reach $5.25 in the next twelve months. View Analyst Ratings for Verastem.

What are analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:

  • 1. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (8/12/2017)
  • 2. Cann analysts commented, "Verastem announced today that scientific findings from two studies evaluating focal adhesion kinase (FAK) inhibition in preclinical models of pancreatic and breast cancer with the publication of two papers in the peer-reviewed journals PLoS One and Oncotarget. The company reported that these two published articles continue to validate its underlying thesis for ongoing clinical collaborations evaluating lead FAK inhibitor defactinib in combination with chemotherapeutic and leading immunotherapeutic agents in several difficult-to-treat cancers." (7/25/2017)
  • 3. Cantor Fitzgerald analysts commented, "DYNAMO Follow-Up Data Coming Soon. VSTM will present follow-up data with duvelisib in double-refractory indolent non-Hodgkin lymphoma (iNHL) at the International Conference on Malignant Melanoma (ICML), commonly referred to as the Lugano Meeting" on June 15th. We think these data could provide support for duvelisib, should the long-term data prove to be durable. Rethinking Duvelisib. Duvelisib’s past history as a development candidate is potentially masking its true market opportunity, as the drug could be used in Imbruvica failures. We don’t view the outcome of the DUO trial as slam dunk", but we do think that the drug’s potential has been overshadowed by its previous history. The drug is being compared to Novartis’ (Not Covered) Arzerra (ofatumumab), and tested in a setting of relapsed/refractory CLL. Optionality with Defactinib. While duvelisib will be the key driver for the value expansion near term, in our view, VSTM is also continuing development of defactinib. Given the prior history of defactinib (COMMAND) it also appears to us that the clinical profile may not be recognized until additional data are in hand, particularly as some of the work is being conducted via investigator- sponsored trials (ISTs)." (5/11/2017)
  • 4. HC Wainwright analysts commented, "According to management, the topline results from the Phase 3 DUO study of duvelisib (a PI3K-??/PI3K-?? inhibitor) for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) are expected around mid-year 2017. Recall, DUO is a 300-patient, randomized, controlled study comparing the use of duvelisib monotherapy to ofatumumab, an anti-CD20 antibody marketed as Arzerra by Novartis (NVS; not rated), for the treatment of CLL, with the primary endpoint of progression-free survival (PFS) and secondary endpoints that include overall response rate (ORR) and overall survival (OS). Based on results from earlier stage studies in CLL as well as the previously completed DYNAMO study in indolent non-Hodgkin's lymphoma (iNHL), we believe that DUO is highly likely to meet its primary PFS endpoint. Furthermore, while many investors have doubts regarding duvelisib's commercial outlook in the competitive CLL indication, we believe that, even with less-than-stellar results from DUO, the drug has the potential to capture a material portion of the highly lucrative market for 2nd/3rd-line CLL treatments. Therefore, we expect positive results from the DUO study to be a significant catalyst for the company. Based on our analysis of duvelisib's commercial potential, we are increasing our price target to $6.50 per diluted share, up from $5.00." (3/24/2017)

Are investors shorting Verastem?

Verastem saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,587,876 shares, an increase of 92.9% from the August 15th total of 823,101 shares. Based on an average daily volume of 493,736 shares, the short-interest ratio is presently 3.2 days. Approximately 5.0% of the shares of the company are short sold.

Who are some of Verastem's key competitors?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:

  • Robert Forrester, President, Chief Executive Officer
  • Julie B. Feder, Chief Financial Officer
  • Daniel W. Paterson, Chief Operating Officer
  • Joseph Chiapponi, Vice President - Finance
  • Monica Kleinman, Vice President, General Counsel
  • Michael Ferraresso, Vice President - Commercial Operations
  • Lori A. Kunkel M.D., Clinical and Scientific Advisory Board
  • Hagop Youssoufian M.Sc., M.D.,, Head - Hematology and Oncology Development
  • Michael G. Kauffman M.D. Ph.D., Lead Independent Director
  • Eric K. Rowinsky M.D., Director

Who owns Verastem stock?

Verastem's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RIDGEBACK CAPITAL INVESTMENTS L.P. (7.70%), Vanguard Group Inc. (3.09%), Artal Group S.A. (1.35%), Stifel Financial Corp (0.99%), Howland Capital Management LLC (0.79%) and Dimensional Fund Advisors LP (0.78%). Company insiders that own Verastem stock include Michael Kauffman and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Who sold Verastem stock? Who is selling Verastem stock?

Verastem's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, AWM Investment Company Inc. and Stifel Financial Corp. View Insider Buying and Selling for Verastem.

Who bought Verastem stock? Who is buying Verastem stock?

Verastem's stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Dimensional Fund Advisors LP, OxFORD Asset Management LLP, Vanguard Group Inc., Alpine Woods Capital Investors LLC, Howland Capital Management LLC and Northern Trust Corp. View Insider Buying and Selling for Verastem.

How do I buy Verastem stock?

Shares of Verastem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of Verastem stock can currently be purchased for approximately $5.15.

MarketBeat Community Rating for Verastem (NASDAQ VSTM)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  323
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Verastem (NASDAQ:VSTM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $5.25 (1.94% upside)

Analysts' Ratings History for Verastem (NASDAQ:VSTM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/7/2017HC WainwrightReiterated RatingBuy -> Buy$6.50 -> $10.00LowView Rating Details
9/6/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$6.00HighView Rating Details
9/6/2017Cantor FitzgeraldUpgradeNeutral -> Overweight$2.00HighView Rating Details
8/16/2017CannReiterated RatingBuyLowView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingHold$1.50HighView Rating Details
4/13/2017CIBCReiterated RatingOutperform -> Outperform$6.00HighView Rating Details
9/29/2015JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
9/29/2015Raymond James Financial, Inc.DowngradeStrong-Buy -> Outperform$12.00 -> $3.00N/AView Rating Details
9/28/2015MizuhoDowngradeBuy -> Neutral$21.00 -> $2.00N/AView Rating Details
9/28/2015Roth CapitalDowngradeBuy -> Neutral$23.00 -> $2.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Verastem (NASDAQ:VSTM)
Earnings by Quarter for Verastem (NASDAQ:VSTM)
Earnings History by Quarter for Verastem (NASDAQ VSTM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.32)N/AView Earnings Details
8/8/2017Q2 2017($0.34)($0.36)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.35)($0.35)ViewN/AView Earnings Details
11/7/2016Q3($0.24)($0.21)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.23)ViewN/AView Earnings Details
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details
11/12/2013Q3($0.44)($0.47)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Verastem (NASDAQ:VSTM)
2017 EPS Consensus Estimate: ($1.40)
2018 EPS Consensus Estimate: ($2.16)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.37)($0.37)($0.37)
Q2 20171($0.36)($0.36)($0.36)
Q3 20171($0.35)($0.35)($0.35)
Q4 20171($0.32)($0.32)($0.32)
Q1 20181($0.42)($0.42)($0.42)
Q2 20181($0.48)($0.48)($0.48)
Q3 20181($0.56)($0.56)($0.56)
Q4 20181($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)


Dividend History for Verastem (NASDAQ:VSTM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Verastem (NASDAQ:VSTM)
Insider Ownership Percentage: 12.00%
Institutional Ownership Percentage: 24.19%
Insider Trades by Quarter for Verastem (NASDAQ:VSTM)
Institutional Ownership by Quarter for Verastem (NASDAQ:VSTM)
Insider Trades by Quarter for Verastem (NASDAQ:VSTM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Timothy J BarberichDirectorBuy30,000$2.45$73,500.00View SEC Filing  
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00View SEC Filing  
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.00View SEC Filing  
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00View SEC Filing  
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00View SEC Filing  
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00View SEC Filing  
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00View SEC Filing  
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00View SEC Filing  
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00View SEC Filing  
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00View SEC Filing  
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00View SEC Filing  
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00View SEC Filing  
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00View SEC Filing  
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00View SEC Filing  
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00View SEC Filing  
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00View SEC Filing  
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00View SEC Filing  
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Verastem (NASDAQ:VSTM)
Latest Headlines for Verastem (NASDAQ:VSTM)
DateHeadline logo-$0.32 Earnings Per Share Expected for Verastem, Inc. (VSTM) This Quarter - September 20 at 4:12 PM logoShort Interest in Verastem, Inc. (VSTM) Grows By 92.9% - September 16 at 1:20 AM logoVerastem, Inc. (VSTM) Receives Average Recommendation of "Hold" from Analysts - September 13 at 8:04 AM logoVerastem, Inc. (VSTM) Stock Rating Reaffirmed by HC Wainwright - September 7 at 11:01 AM logoVerastem Boosted After Positive Top-Line Data For Leukemia Treatment - September 7 at 10:58 AM logoToday's Research Reports on Stocks to Watch: Moleculin Biotech and Verastem - September 7 at 10:58 AM logoOppenheimer Holdings, Inc. Reaffirms Buy Rating for Verastem, Inc. (VSTM) - September 6 at 3:56 PM logoVerastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO™ Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma - September 6 at 10:02 AM logoCantor Fitzgerald Upgrades Verastem, Inc. (VSTM) to "Overweight" - September 6 at 9:33 AM logoValuEngine Downgrades Verastem Inc (VSTM) to Sell - September 2 at 12:06 AM logoVerastem, Inc. (VSTM) Short Interest Down 48.9% in August - August 28 at 1:20 AM logoImplied Volatility Surging for Verastem (VSTM) Stock Options - August 19 at 8:54 AM logoVerastem, Inc. (VSTM) Given Consensus Rating of "Hold" by Analysts - August 19 at 6:50 AM logoVerastem's (VSTM) "Buy" Rating Reaffirmed at Cann - August 16 at 8:26 PM logoVerastem, Inc. (NASDAQ:VSTM) Expected to Announce Earnings of -$0.32 Per Share - August 14 at 2:30 PM logoVerastem, Inc. (NASDAQ:VSTM) Sees Large Growth in Short Interest - August 13 at 1:46 AM logoVerastem, Inc. (VSTM) Cut to "Sell" at Zacks Investment Research - August 12 at 11:14 AM logoVerastem, Inc. to Post Q3 2017 Earnings of ($0.35) Per Share, Oppenheimer Holdings Forecasts (VSTM) - August 11 at 7:48 AM logoVerastem, Inc. (NASDAQ:VSTM) Announces Quarterly Earnings Results - August 9 at 2:35 PM logoVerastem Reports Second Quarter 2017 Financial Results - Business Wire (press release) - August 9 at 8:59 AM logoVerastem Reports Second Quarter 2017 Financial Results - August 9 at 8:59 AM logoVerastem, Inc. (NASDAQ:VSTM) Scheduled to Post Earnings on Monday - July 31 at 8:16 AM logoVerastem, Inc. (NASDAQ:VSTM) Expected to Post Earnings of -$0.34 Per Share - July 27 at 10:35 AM logoVerastem Shows Long-Term Potential With Strong DYNAMO Data - Seeking Alpha - July 26 at 9:52 AM logoVerastem, Inc. (VSTM) Given Consensus Recommendation of "Buy" by Brokerages - July 25 at 8:43 AM logoVerastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer - Business Wire (press release) - July 25 at 8:19 AM logoVerastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer - July 25 at 8:19 AM logoVerastem Inc (NASDAQ:VSTM) Rating Lowered to Hold at Zacks Investment Research - July 18 at 12:13 PM logoExclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock - Benzinga - July 18 at 9:51 AM logoVerastem Inc (NASDAQ:VSTM) Rating Increased to Buy at Zacks Investment Research - July 13 at 4:08 PM logoVerastem continues up move, shares ahead 20% - July 11 at 2:46 PM logoCompany Spotlight: Verastem - Nasdaq - July 8 at 9:52 PM logoGainers & Losers Of July 6: VSTM, BGNE, ALRN, TXMD, OCUL... - July 8 at 4:50 PM logoVerastem (VSTM) Shows Strength: Stock Adds 42% in Session - July 8 at 4:50 PM logo-$0.34 Earnings Per Share Expected for Verastem Inc (NASDAQ:VSTM) This Quarter - July 3 at 8:35 AM logoVerastem's (VSTM) Hold Rating Reiterated at Jefferies Group LLC - June 28 at 11:28 AM logoVerastem Inc (VSTM) Given Consensus Rating of "Buy" by Analysts - June 28 at 8:08 AM logoVerastem's (VSTM) "Buy" Rating Reiterated at Cann - June 26 at 8:34 AM logoResearch Analysts Offer Predictions for Verastem Inc's FY2018 Earnings (VSTM) - June 26 at 7:51 AM logoVerastem Reports Phase 2 Long-Term Follow-Up Data For Duvelisib - Quick Facts - June 25 at 11:05 PM logoVerastem Reports Phase 2 Long-Term Follow-Up Data for Duvelisib in Patients with Double-Refractory Follicular Lymphoma and Small Lymphocytic Lymphoma at the 22nd Congress of the European Hematology Association - June 25 at 7:24 AM logoVerastem Inc (VSTM) Rating Reiterated by Cantor Fitzgerald - June 8 at 8:02 AM logoVerastem (VSTM) Present Long-Term Follow-Up Data from the DYNAMO Study at ICML - June 8 at 1:56 AM logoVerastem to Present Long-Term Follow-Up Data from the DYNAMO™ Study at the 14th International Conference on Malignant Lymphoma - June 8 at 1:56 AM logo-$0.34 EPS Expected for Verastem Inc (VSTM) This Quarter - June 7 at 8:06 AM logoVerastem Inc (VSTM) Given a $6.00 Price Target at Oppenheimer Holdings Inc. - June 5 at 8:42 PM logoVerastem Inc (VSTM) Given Consensus Recommendation of "Buy" by Brokerages - June 2 at 8:32 PM logoVerastem to Present at the Jefferies 2017 Global Healthcare Conference - May 31 at 11:38 AM logoVerastem Inc (VSTM) Upgraded by Zacks Investment Research to "Hold" - May 25 at 7:28 AM logoVerastem (VSTM) Announces Duvelisib Data Presentations at EHA - - May 19 at 1:39 PM



Verastem (VSTM) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff